Document is current
Any future updates will be listed below
-
Authors
Peixoto Pinheiro, Barbara http://orcid.org/0000-0001-7347-7975
Müller, Marcus
Bös, Michael
Guezguez, Jamil
Burnet, Michael
Tornincasa, Mara
Rizzetto, Riccardo
Rolland, Jean-Francois
Liberati, Chiara
Lohmer, Stefan
Adel, Youssef http://orcid.org/0000-0002-8968-5995
Löwenheim, Hubert http://orcid.org/0000-0001-8200-8804
-
Funding
Funding for this research was provided by:
Acousia Therapeutics, 72070 Tübingen, Germany
- License Information
-
More Information
Article History
Received: 7 February 2022
Revised: 29 April 2022
Accepted: 4 May 2022
First Online: 11 July 2022
Ethical approval
: Animal care, treatments, and procedures were performed according to the German (TierSchG) and European Union (directive 2010/63/EU) guidelines for the protection of animals used for experimental purposes, following revision and approval by the veterinary care unit of the University of Tübingen and the regional animal care and ethics committee (Regierungspräsidium Tübingen, approval no. HN3/17).
: M Bös (deceased) was the former Chief Scientific Officer of Acousia Therapeutics (Tübingen, Germany) and inventor of the composition of matter and use of ACOU085 and related compounds, filed and assigned to Acousia Therapeutics [CitationRef removed]. SL is shareholder and member of the board of directors, and HL is scientific founder, shareholder, and member of the board of directors of Acousia Therapeutics. This study and the salary of BP were in part financed under a master service agreement between the University of Tübingen Medical Center (Universitätsklinikum Tübingen, Tübingen, Germany) and Acousia Therapeutics. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
